2022 Abstracts


The World Cancer Congress is the ideal place for key players in the cancer community to present their work to a global audience. Whether you are a renowned scientist, an experienced advocate, or a master in raising funds for the cause, we want to hear from you!

The call for abstracts ran from 14 February until 15 April 2022 and closed on a high note with over 1,530 submissions received.

Top 5 reasons to SUBMIT AN ABSTRACT and be part of a world-class programme

  1. Present your work at an award-winning conference and contribute to accelerating progress in the global fight against cancer
  2. Shine a light on your work and showcase your expertise to a global multi-sectoral audience
  3. Profile your experience, your organisation and your impactful achievements on a powerful platform
  4. Receive valuable feedback and return home with some new perspectives
  5. Share best practices with your peers from around the world and make useful connections

New at 2022 World Cancer Congress: Nomination to UICC Awards

The UICC Awards aim to recognize outstanding achievements and innovative practices from across the global cancer community

The three abstracts with the highest scores from each category will be shortlisted prior to the event and highlighted in the Congress promotional campaign. The winner from each list will be presented with an award at the World Cancer Congress in Geneva. 



"My participation broadened my outlook and lectures were varied, the presentation of my abstract gave me an opportunity to present, and I was happy that my presentation was well received and appreciated"

Delegate via 2018 WCC Survey

Submission categories

Three types of submission are welcomed at the Congress:

  1. Abstracts on scientific studies describing the collection, analysis and interpretation of cancer-relevant data (clinical, behavioural, epidemiological, etc)
  2. Summaries of practice, policy and advocacy reports with impact describing innovative cancer and NCD programmes in detection, care, support, prevention, organisation.
  3. Summaries of fundraising campaign reports describing programmes to build public support to fund or donate to cancer and NCD control causes.

Submission guidelines

  1. All submissions should be made in English and only through the online submission platform. Abstracts submitted in another language than English will be automatically rejected.
  2. The abstract must contain at least 1'500 characters and cannot contain more than 3’000 characters (blank spaces, punctuation as well as authors’ affiliation and titles included). 
  3. A prescribed format has been identified for each type of submission format:
    • Scientific studies. Background, aim, methods, results, conclusions.
    • Practice, policy and advocacy reports. Background and context, aim, strategy/tactics, programme/policy process, outcomes, what was learnt (develop any replicability potential)
    • Fundraising campaign reports. Amount raised, background and context, aim, strategy/tactics, programme process, stakeholders involved, costs and returns, innovative methods, what was learnt. Mention any replicability potential.
  4. Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are possible after the submission. The abstract will be reproduced exactly as submitted. Please ensure that the abstract is complete. No proofreading will be done.
  5. Abstracts should meet international ethical standards.
  6. Abbreviations should be defined.
  7. All graphics and supporting visuals need to be commented and with an explanatory title.
  8. The submitting author accepts to declare all of the authors’ conflicts of interest for the last 5 years. An abstract or summary report cannot be accepted if the conflict-of-interest disclosure has not been ticked on the submission form. If the project or one of the co-authors has a conflict of interest, this must be clearly stated within the submission form and then, later, upon acceptance of the abstract, disclosed within the presentation.
  9. Each author needs to have authorized the submitter to submit the abstract, and then, later, upon acceptance of the abstract, approved to have it presented at the Congress. The submission system will require co-authors details to notify them of the abstract submission.
  10. Please ensure to mention all sources of information and references.
  11. Once you have successfully submitted your abstract, you will receive a confirmation email with an abstract ID number, to use in any communication you might have with the organisers.
  12. Abstracts can be re-edited and modified until you click “submit” for final submission. Once submitted, abstracts cannot be edited.
  13. All abstracts should be finalised and submitted by 15 April 2022 at midnight CET.
  14. As a result of the abstract review phase 1, all submitters will receive a notification of acceptance or rejection of their abstract on 19 April 2022.
  15. As a result of the abstract review phase 2, on 15 July 2022, all submitters will receive a notification of their format of presentation.
  16. Before 16 September, all accepted abstract will have to either:
    • fully register, if selected for an in-person presentation at the World Cancer Congress in Geneva. A full registration also gives the right to have the accepted abstract published in the eLibrary on the online platform.
    • or purchase a digital pass for the online platform if the accepted abstract is to feature in the abstract eLibrary only
    • A presenter that has not registered or purchased a digital pass by 16 September will have their abstract withdrawn from the programme and abstract eLibrary.

Formats of presentation

All accepted abstracts will be available in the abstract eLibrary hosted on the dedicated Congress online platform.

By 15th July, all submitters will be notified of the format of presentation of their accepted abstract. The selection is based on the average score received. As a result, some abstracts and summary reports will be presented in-person at the World Cancer Congress, under one of the following presentation formats:

  1. Abstract oral: 8-minute in-person presentation (incl. 2 minutes of Question and Answers from the in-person audience). Abstract oral presentations are part of a larger session and will be scheduled for presentation in front of an audience of up to 80 people.
    Before 16 September:
    ​​​​Abstract presenters from this category must purchase a registration to attend the Congress in-person in Geneva.
  2. Rapid Fire: 3-minute presentation in front of an audience of up to 80 people.
    Before 16 September:
    Abstract presenters from this category must purchase a registration to present at the Congress in person in Geneva. In addition to the on-site presentation, the accepted abstract will be part of the abstract eLibrary available on the online platform, and for self-consultation in the Theme Pavillions of the Global Village.
  3. Inclusion in the abstract eLibrary + meeting facility: The abstract eLibrary will be hosted on the online platform.
    Before 16 September, submitters and authors whom wish to have their accepted abstracts part of the abstract eLibrary will need to either purchase a registration if they wish to attend the Congress in-person in Geneva, or a digital access if they cannot travel to Geneva and only wish to only have their abstract available in the abstract eLibrary. 

    Connect pro-actively: UICC would like to encourage useful connections and new collaborations amongst participants. All submitters are invited to use the online platform to set-up meetings with other participants to present their work to them. Meetings can be set-up and conducted virtually either directly through the online platform or in-person in Geneva, in one of the lounge areas of the Congress. 

Review Process and Timeline

The review process is based on an independent two-tier review process from the Congress Abstract Committee and an international panel of health experts.

  • 14 February – 15 April 2022: Call for Abstracts & Abstract Review Phase 1

Submissions have been screened by the Abstract Committee, and all submitters have been notified if the abstract has been accepted or rejected.

  • 2 May – 1 June 2022: Abstract Review Phase 2

Accepted abstracts have been scored by the Abstract Committee, supported by a selected panel of 130+ experts.

  • 15 July 2022: Notification of presentation format and time slot to all accepted abstract submitters
  • 16 September 2022: All abstract presenters confirmed with a full registration or digital pass for inclusion in the abstract eLibrary.


The International Atomic Energy Agency (IAEA) will be providing a reduced number of travel grants for active participants at the Congress, from national public entity or civil society organisations based in IAEA's member states. Submitting an abstract (accepted) is part of the selection criteria. Please check the details of the selection criteria, application process and timeline to benefit from this opportunity.

For any questions regarding the abstracts, please contact Céline Francina at francina@uicc.org. Thank you!